---
layout: default
title: Prednisolone
description: "Prednisolone çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚ä¸­ç­‰è­‰æ“šç­‰ç´š L3ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 138
evidence_level: L1
indication_count: 10
---

# Prednisolone

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L3</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Prednisoloneï¼šå¾æ¿•ç–¹æ¨£çš®è†šç‚åˆ°æ–‘ç¦¿ (Alopecia Areata)

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Prednisolone å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Prednisolone åŸæœ¬ç”¨æ–¼æ²»ç™‚æ¿•ç–¹æ¨£çš®è†šç‚ç­‰éæ•æ€§æˆ–ç™¼ç‚æ€§çš®è†šç–¾æ‚£ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**æ–‘ç¦¿ (Alopecia Areata)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **14 å€‹è‡¨åºŠè©¦é©—**å’Œ **8 ç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | æ¿•ç–¹æ¨£çš®è†šç‚ã€èŸ²å’¬å‚·ã€å°¿å¸ƒç–¹ã€çš®è†šæ”ç™¢åŠéæ•æ€§æˆ–ç™¼ç‚æ€§çš®è†šç–¾æ‚£ç­‰ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | alopecia areataã€alopecia mucinosaã€telogen effluviumã€Quinquaud's folliculitis decalvansã€alopecia antibody deficiencyã€hereditary hypotrichosis with recurrent skin vesiclesã€alopecia-intellectual disability-hypergonadotropic hypogonadism syndromeã€atrichia with papular lesionsã€prolapse of lacrimal glandã€Sjogren syndrome |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.99% |
| è­‰æ“šç­‰ç´š | L3 |
| å°ç£ä¸Šå¸‚ | âœ“ å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 20 å¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. alopecia areata</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.99%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p><p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ"></p>
<p>ç›®å‰ç¼ºä¹è©³ç´°çš„ä½œç”¨æ©Ÿè½‰è³‡æ–™ã€‚æ ¹æ“šå·²çŸ¥è³‡è¨Šï¼ŒPrednisolone æ˜¯ä¸€ç¨®é¡å›ºé†‡è—¥ç‰©ï¼Œå…·æœ‰æŠ—ç‚å’Œå…ç–«èª¿ç¯€ä½œç”¨ã€‚</p>
<p>å…¶æˆåˆ†åœ¨æ²»ç™‚éæ•æ€§å’Œç™¼ç‚æ€§çš®è†šç–¾ç—…ä¸­çš„ç™‚æ•ˆå·²è¢«è­‰å¯¦ï¼Œæ©Ÿè½‰ä¸Šå¯èƒ½é©ç”¨æ–¼æ–‘ç¦¿é€™é¡è‡ªé«”å…ç–«æ€§ç–¾ç—…ã€‚</p>
<p></p></p>

<p><div class="key-takeaway"></p>
<p>æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<table>
<thead>
<tr>
<th>è©¦é©—ç·¨è™Ÿ</th>
<th>éšæ®µ</th>
<th>ç‹€æ…‹</th>
<th>äººæ•¸</th>
<th>ä¸»è¦ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT03616964">NCT03616964</a></td>
<td>Phase 3</td>
<td>å®Œæˆ</td>
<td>778</td>
<td>ç ”ç©¶ Baricitinib åœ¨ SLE æ‚£è€…ä¸­çš„æ•ˆæœå’Œå®‰å…¨æ€§ã€‚</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT05162586">NCT05162586</a></td>
<td>Phase 2</td>
<td>å®Œæˆ</td>
<td>456</td>
<td>ç ”ç©¶ Enpatoran åœ¨ SLE å’Œ CLE æ‚£è€…ä¸­çš„æ•ˆæœå’Œå®‰å…¨æ€§ã€‚</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT04835441">NCT04835441</a></td>
<td>Phase 2</td>
<td>å®Œæˆ</td>
<td>76</td>
<td>ç ”ç©¶ ALPN-101 åœ¨ä¸­é‡åº¦ SLE æ‚£è€…ä¸­çš„æ•ˆæœã€‚</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT03843125">NCT03843125</a></td>
<td>Phase 3</td>
<td>çµ‚æ­¢</td>
<td>1147</td>
<td>é•·æœŸç ”ç©¶ Baricitinib åœ¨ SLE æ‚£è€…ä¸­çš„æ•ˆæœå’Œå®‰å…¨æ€§ã€‚</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT07101471">NCT07101471</a></td>
<td>N/A</td>
<td>å®Œæˆ</td>
<td>296</td>
<td>è©•ä¼° RhofanibÂ® (Tofacitinib) åœ¨æ–‘ç¦¿æ‚£è€…ä¸­çš„å®‰å…¨æ€§å’Œæ•ˆæœã€‚</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT01167946">NCT01167946</a></td>
<td>Phase 4</td>
<td>å®Œæˆ</td>
<td>42</td>
<td>ç ”ç©¶å¤§åŠ‘é‡å£æœé¡å›ºé†‡åœ¨åš´é‡æ–‘ç¦¿ä¸­çš„å®‰å…¨æ€§å’Œæ•ˆæœã€‚</td>
</tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»</h3>

<table>
<thead>
<tr>
<th>PMID</th>
<th>å¹´ä»½</th>
<th>é¡å‹</th>
<th>æœŸåˆŠ</th>
<th>ä¸»è¦ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/37870096/">37870096</a></td>
<td>2023</td>
<td>Meta-analysis</td>
<td>The Cochrane database of systematic reviews</td>
<td>æ–‘ç¦¿çš„æ²»ç™‚åŒ…æ‹¬å…ç–«æŠ‘åˆ¶åŠ‘ã€ä¿ƒé€²æ¯›é«®ç”Ÿé•·çš„è—¥ç‰©å’Œæ¥è§¸å…ç–«ç™‚æ³•ã€‚</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/30191561/">30191561</a></td>
<td>2019</td>
<td>Systematic Review</td>
<td>The Australasian journal of dermatology</td>
<td>ç³»çµ±æ€§æ²»ç™‚åœ¨æ–‘ç¦¿ä¸­çš„æ‡‰ç”¨åŠå…¶æ•ˆæœã€‚</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/37992355/">37992355</a></td>
<td>2023</td>
<td>Review</td>
<td>Dermatology practical & conceptual</td>
<td>ç ”ç©¶é¡å›ºé†‡è„ˆè¡ç™‚æ³•åœ¨æ–‘ç¦¿ä¸­çš„æ•ˆæœåŠå‰¯ä½œç”¨ã€‚</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/35986630/">35986630</a></td>
<td>2022</td>
<td>Retrospective Study</td>
<td>Dermatologic therapy</td>
<td>ç ”ç©¶ç”²åŸºå¼·çš„æ¾é¾å–®ç¨æˆ–èˆ‡ç”²æ°¨è¶å‘¤è¯åˆæ²»ç™‚å»£æ³›æ–‘ç¦¿çš„æ•ˆæœã€‚</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/15692475/">15692475</a></td>
<td>2005</td>
<td>RCT</td>
<td>Journal of the American Academy of Dermatology</td>
<td>ç³»çµ±æ€§é¡å›ºé†‡ä½œç‚ºè„ˆè¡ç™‚æ³•åœ¨æ–‘ç¦¿ä¸­çš„æ‡‰ç”¨ã€‚</td>
</tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. alopecia mucinosa</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ5 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40657655/" target="_blank">40657655</a></td><td>2024</td><td>Article</td><td>Acta dermatovenerolo</td><td>A Case of Idiopathic Follicular Mucinosis Treated Successful...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10215785/" target="_blank">10215785</a></td><td>1999</td><td>Article</td><td>The British journal </td><td>Pilotropic mycosis fungoides presenting with multiple cysts,...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9310735/" target="_blank">9310735</a></td><td>1997</td><td>Article</td><td>Dermatology (Basel, </td><td>Follicular mucinosis and systemic lupus erythematosus.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20141606/" target="_blank">20141606</a></td><td>2010</td><td>Article</td><td>Veterinary dermatolo</td><td>Canine cutaneous epitheliotropic T-cell lymphoma: a review o...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4278795/" target="_blank">4278795</a></td><td>1974</td><td>Article</td><td>Zeitschrift fur Haut</td><td>[Follicular mucinosis and large area, partly lichenoid, part...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. telogen effluvium</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ1 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31056741/" target="_blank">31056741</a></td><td>2019</td><td>Article</td><td>The Australasian jou</td><td>Alopecia in Cronkhite-Canada syndrome: Is it truly telogen e...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. Quinquaud&#x27;s folliculitis decalvans</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ2 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17982613/" target="_blank">17982613</a></td><td>2006</td><td>Article</td><td>Acta dermatovenerolo</td><td>Folliculitis decalvans of the scalp: response to triple ther...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10886161/" target="_blank">10886161</a></td><td>2000</td><td>Article</td><td>The British journal </td><td>Simultaneous occurrence of folliculitis decalvans capillitii...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. alopecia antibody deficiency</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ3 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36117202/" target="_blank">36117202</a></td><td>2022</td><td>Article</td><td>Allergy, asthma, and</td><td>Systemic lupus erythematosus with various clinical manifesta...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30099593/" target="_blank">30099593</a></td><td>2018</td><td>Article</td><td>Rheumatology interna</td><td>Lupus anticoagulant hypoprothrombinemia syndrome associated ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19433284/" target="_blank">19433284</a></td><td>2009</td><td>Article</td><td>Pediatric neurology</td><td>Rasmussen syndrome combined with IgA deficiency and membrano...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. hereditary hypotrichosis with recurrent skin vesicles</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. atrichia with papular lesions</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. prolapse of lacrimal gland</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. idiopathic steroid-sensitive nephrotic syndrome</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.86%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ8 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07233330" target="_blank">NCT07233330</a></td><td>PHASE2</td><td>NOT_YET_RECRUITING</td><td>10</td><td>Obinutuzumab Treatment in Frequently Relapsing and Rituximab-Dependent Idiopathi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04783675" target="_blank">NCT04783675</a></td><td>PHASE2</td><td>COMPLETED</td><td>44</td><td>Efficacy and Safety of Rituximab in the First Episode of Pediatric Idiopathic Ne...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04818723" target="_blank">NCT04818723</a></td><td>NA</td><td>COMPLETED</td><td>106</td><td>Role of Montelukast in Preventing Relapse in Childhood Idiopathic Nephrotic Synd...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05044169" target="_blank">NCT05044169</a></td><td>NA</td><td>UNKNOWN</td><td>83</td><td>Efficacy and Safety of Broncho-Vaxom in Reducing Recurrence in Children With Ste...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06635720" target="_blank">NCT06635720</a></td><td>PHASE3</td><td>RECRUITING</td><td>50</td><td>REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE): a Pil...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 3 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33478977/" target="_blank">33478977</a></td><td>2021</td><td>Article</td><td>Clinical journal of </td><td>Steroid Regimen for Children with Nephrotic Syndrome Relapse...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40337980/" target="_blank">40337980</a></td><td>2025</td><td>Article</td><td>The Cochrane databas</td><td>Interventions for idiopathic steroid-resistant nephrotic syn...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30342869/" target="_blank">30342869</a></td><td>2018</td><td>Article</td><td>The Lancet. Child &amp; </td><td>Management of steroid-resistant nephrotic syndrome in childr...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27726125/" target="_blank">27726125</a></td><td>2016</td><td>Article</td><td>The Cochrane databas</td><td>Interventions for idiopathic steroid-resistant nephrotic syn...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34925975/" target="_blank">34925975</a></td><td>2021</td><td>Article</td><td>Cureus</td><td>Management of Steroid-Resistant Nephrotic Syndrome in Childr...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| å…§è¡›è—¥è£½å­—ç¬¬000590è™Ÿ | æ¨‚çˆ¾çˆ½è»Ÿè† | è»Ÿè†åŠ‘ | æ¿•ç–¹æ¨£çš®è†šç‚ã€èŸ²å’¬å‚·ã€å°¿å¸ƒç–¹ã€çš®è†šæ”ç™¢åŠéæ•æ€§æˆ–ç™¼ç‚æ€§çš®è†šç–¾æ‚£ç­‰ |
| å…§è¡›è—¥è£½å­—ç¬¬000711è™Ÿ | æ™®åŠ›å¤šå¯§éŒ  | éŒ åŠ‘ | é¢¨æ¿•æ€§ç–¾æ‚£ã€æ”¯æ°£ç®¡æ°£å–˜ã€è…ç‚ç—‡å€™ç¾¤ã€éæ•æ€§çš®è†šç–¾æ‚£ |
| å…§è¡›è—¥è£½å­—ç¬¬004492è™Ÿ | â€œè¯ç³â€è¢ªé¢¨æ¿•é¾éŒ  | éŒ åŠ‘ | é¢¨æ¿•æ€§é—œç¯€ç‚ã€çš®è†šç‚ã€æ”¯æ°£ç®¡ç‚ã€æ°£å–˜ã€éæ•æ€§ç–¾æ‚£ |

## å®‰å…¨æ€§è€ƒé‡

- **è—¥ç‰©äº¤äº’ä½œç”¨**ï¼šPrednisolone èˆ‡å¤šç¨®è—¥ç‰©æœ‰ä¸­ç­‰ç¨‹åº¦çš„äº¤äº’ä½œç”¨ï¼Œä¾‹å¦‚ Zidovudineã€Abametapir (topical)ã€Isotretinoin ç­‰ã€‚
- **ä¸»è¦äº¤äº’ä½œç”¨**ï¼šèˆ‡ Adalimumab æœ‰é‡å¤§äº¤äº’ä½œç”¨ã€‚

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**ç”˜è‰** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šç”˜è‰å»¶é•·çš®è³ªé¡å›ºé†‡ä½œç”¨ï¼Œå¢åŠ å‰¯ä½œç”¨é¢¨éšª
- å»ºè­°ï¼šé¿å…é«˜åŠ‘é‡ç”˜è‰


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Latent Tuberculosis** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

**Fibrosis** ğŸŸ¡ Moderate
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚

**Psychotic Disorders** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

**ç³–å°¿ç—…** ğŸŸ¡ Moderate
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šé«˜è¡€ç³–ã€‚

**Water-Electrolyte Imbalance** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šç™²ç™‡ç™¼ä½œã€‚

**Water-Electrolyte Imbalance** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šCorticosteroids may cause hypernatremia, hypokalemia, fluid retention, and elevation in blood pressure...

**Peptic Ulcer Perforation** ğŸŸ¡ Moderate
- æ‡‰é¿å…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šå‡ºè¡€ã€æ„ŸæŸ“ã€‚

**Cushing Syndrome** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šCorticosteroids mimic the effects of endogenous cortisol and aldosterone...

**Hyperlipidemias** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

**ç”²ç‹€è…ºæ©Ÿèƒ½ä½ä¸‹** ğŸŸ¡ Moderate
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚

**Myocardial Infarction** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

**é‡ç—‡è‚Œç„¡åŠ›** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Muscular Diseases** ğŸŸ¡ Moderate
- å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Keratitis, Herpetic** ğŸŸ¡ Moderate
- ä¸å»ºè­°ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

**Toxic Optic Neuropathy** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šProlonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma...

**éª¨è³ªç–é¬†ç—‡** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šCorticosteroids reduce osteoblastic function and inhibit the absorption of intestinal calcium, which can result in bone resorption and bone loss durin...

**æ¶ˆåŒ–æ€§æ½°ç˜** ğŸŸ¡ Moderate
- æ‡‰é¿å…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šå‡ºè¡€ã€‚

**Scleroderma, Localized** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šIn patients with scleroderma, corticosteroids may precipitate renal crisis with malignant hypertension, possibly via steroid-induced increases in reni...

**Strongyloidiasis** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šæ„ŸæŸ“ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚

**Thromboembolism** ğŸŸ¡ Moderate
- é¢¨éšªåŒ…æ‹¬ï¼šè¡€æ “ã€‚

**Infections** ğŸŸ¢ Minor
- ä¸æ‡‰ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šæ„ŸæŸ“ã€‚å¯èƒ½å±åŠç”Ÿå‘½ã€‚

**Premature Birth** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚ç‰¹åˆ¥æ³¨æ„æ—ç¾¤ï¼šå…’ç«¥ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
Prednisolone åœ¨æ–‘ç¦¿çš„æ²»ç™‚ä¸­å·²æœ‰å¤šå€‹è‡¨åºŠè©¦é©—å’Œæ–‡ç»æ”¯æŒï¼Œé¡¯ç¤ºå…¶å¯èƒ½çš„ç™‚æ•ˆå’Œå®‰å…¨æ€§ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- é€²ä¸€æ­¥çš„æ©Ÿè½‰ç ”ç©¶ä»¥ç¢ºèªå…¶åœ¨æ–‘ç¦¿ä¸­çš„ä½œç”¨æ©Ÿåˆ¶
- ç‰¹å®šæ—ç¾¤çš„å®‰å…¨æ€§ç›£æ¸¬è¨ˆç•«

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Human Immunoglobulin G]({{ "/drugs/human_immunoglobulin_g/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Durvalumab]({{ "/drugs/durvalumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Lornoxicam]({{ "/drugs/lornoxicam/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Dupilumab]({{ "/drugs/dupilumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Interferon Beta-1B]({{ "/drugs/interferon_beta-1b/" | relative_url }}) - è­‰æ“šç­‰ç´š L3

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Prednisoloneè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/prednisolone/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_prednisolone,
  title = {Prednisoloneè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/prednisolone/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
